Columbia Laboratories CEO Acquires $59,800 in Stock (CBRX)
Columbia Laboratories (NASDAQ:CBRX) CEO Frank Condella, Jr. bought 10,000 shares of the stock on the open market in a transaction dated Wednesday, August 13th. The stock was purchased at an average cost of $5.98 per share, for a total transaction of $59,800.00. Following the completion of the transaction, the chief executive officer now directly owns 55,345 shares in the company, valued at approximately $330,963. The transaction was disclosed in a filing with the SEC, which is available at this link.
Columbia Laboratories (NASDAQ:CBRX) traded up 0.34% on Thursday, hitting $5.98. 39,753 shares of the company’s stock traded hands. Columbia Laboratories has a 52 week low of $5.59 and a 52 week high of $8.37. The stock’s 50-day moving average is $6.28 and its 200-day moving average is $6.66. The company has a market cap of $64.4 million and a P/E ratio of 30.10.
Columbia Laboratories (NASDAQ:CBRX) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.01 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.11 by $0.10. On average, analysts predict that Columbia Laboratories will post $0.16 earnings per share for the current fiscal year.
Columbia Laboratories, Inc (NASDAQ:CBRX) focuses on developing products that utilize its bioadhesive drug delivery technologies to optimize drug delivery in a controlled, sustained manner.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.